Altraz: Advanced Aromatase Inhibition for Hormone-Sensitive Breast Cancer
Altraz
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $6.47 | $194.00 (0%) | 🛒 Add to cart |
| 60 | $5.28 | $388.00 $317.00 (18%) | 🛒 Add to cart |
| 90 | $4.90
Best per pill | $582.00 $441.00 (24%) | 🛒 Add to cart |
Synonyms | |||
Altraz (anastrozole) is a potent, non-steroidal aromatase inhibitor indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It represents a cornerstone in endocrine therapy, specifically designed to suppress estrogen synthesis by inhibiting the aromatase enzyme, thereby reducing the proliferation of estrogen-dependent tumor cells. Its targeted mechanism offers a sophisticated approach to hormonal manipulation with a well-established efficacy and safety profile in clinical oncology.
Features
- Contains 1 mg of anastrozole per tablet
- Non-steroidal, selective aromatase inhibitor
- Oral administration with high bioavailability
- Demonstrated specificity for the aromatase enzyme complex
- Manufactured under strict pharmaceutical quality control standards
- Available in blister packs of 28 tablets
Benefits
- Significantly reduces the risk of disease recurrence in hormone-sensitive early breast cancer
- Lowers systemic estrogen levels to near-undetectable concentrations in postmenopausal patients
- Improves disease-free survival and overall survival rates in adjuvant settings
- Offers a favorable side effect profile compared to earlier-generation hormonal therapies
- Convenient once-daily dosing supports treatment adherence
- Does not require concomitant corticosteroid administration
Common use
Altraz is primarily prescribed as adjuvant therapy for postmenopausal women with hormone receptor-positive early breast cancer following primary treatment with surgery or radiation. It is also used as first-line treatment for advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women. Additionally, it may be employed as extended adjuvant therapy following initial tamoxifen treatment, and occasionally used for estrogen suppression in fertility treatments or gynecological conditions under specialist supervision.
Dosage and direction
The recommended dosage is one 1 mg tablet taken orally once daily, with or without food. Tablets should be swallowed whole with water and not crushed or chewed. Treatment typically continues for 5 years in the adjuvant setting, though duration may be modified based on individual risk assessment and tolerability. For advanced breast cancer, treatment continues until disease progression or unacceptable toxicity occurs. Patients should maintain consistent dosing timing to ensure stable drug concentrations.
Precautions
Regular monitoring of bone mineral density is recommended due to accelerated bone loss. Assessment of lipid profiles may be warranted in patients with pre-existing hyperlipidemia. Hepatic function should be monitored in patients with pre-existing liver impairment. Use with caution in patients with moderate to severe renal impairment. Patients should be advised about potential effects on cholesterol levels and cardiovascular health. Concomitant use with other medications that affect CYP3A4 metabolism requires careful consideration.
Contraindications
Altraz is contraindicated in premenopausal women, pregnant women, and nursing mothers. It should not be used in patients with known hypersensitivity to anastrozole or any component of the formulation. Contraindicated in patients with severe hepatic impairment. Not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min). Should not be administered concurrently with estrogen-containing therapies.
Possible side effects
Common adverse reactions (>10%) include hot flashes, arthralgia, arthritis, asthenia, pain, nausea, headache, back pain, and increased cough. Less frequent effects (1-10%) comprise osteoporosis, fractures, peripheral edema, depression, insomnia, rash, hypertension, and vaginal dryness. Rare events (<1%) may include carpal tunnel syndrome, leukopenia, thrombocytopenia, hepatitis, and hypersensitivity reactions. Most side effects are mild to moderate and often diminish with continued therapy.
Drug interaction
Altraz may interact with tamoxifen, potentially reducing anastrozole concentrations. Estrogen-containing therapies may diminish its therapeutic effect. Medications that induce CYP3A4 (e.g., rifampicin, phenytoin) may decrease anastrozole concentrations. Concurrent use with other aromatase inhibitors is not recommended. Caution advised with drugs that affect bone metabolism (e.g., corticosteroids). Potential interactions with tamoxifen may reduce overall efficacy when used concomitantly.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. Maintain consistent daily timing to ensure optimal therapeutic effect. Patients should inform their healthcare provider about pattern of missed doses during follow-up visits.
Overdose
There is limited experience with Altraz overdose. Single doses up to 60 mg have been administered without serious adverse effects. Expected manifestations may include nausea, vomiting, and dizziness. Management should involve supportive care and symptomatic treatment. Gastric lavage may be considered if ingestion occurred recently. No specific antidote exists. Dialysis is unlikely to be effective due to high protein binding. Medical supervision is recommended for any suspected overdose.
Storage
Store at room temperature (15-30°C/59-86°F) in the original container. Protect from light and moisture. Keep blister strips sealed until use. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Properly dispose of any unused medication according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional familiar with the patient’s specific medical history and current condition. Dosage and administration may vary based on individual patient factors. Always follow the prescribing information provided with the medication and the guidance of your treating physician.
Reviews
Clinical trials demonstrate Altraz’s significant efficacy in reducing breast cancer recurrence, with the ATAC trial showing a 24% reduction in risk compared to tamoxifen. Oncologists report high satisfaction with its predictable pharmacokinetics and manageable side effect profile. Patients appreciate the once-daily dosing convenience, though some note challenges with arthralgia and bone health management. Long-term follow-up data confirms sustained benefit over 10-year periods, establishing it as a standard of care in appropriate patient populations.